Stick With Gilead Sciences, Inc. (GILD). The Bull Are Alive And Well

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.

However, the script later moved the day high at 75.32, down -1.08%. The company’s stock has a 5-day price change of -0.68% and -11.01% over the past three months. GILD shares are trading -11.01% year to date (YTD), with the 12-month market performance down to -11.49% lower. It has a 12-month low price of $71.37 and touched a high of $87.86 over the same period. GILD has an average intraday trading volume of 7.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.01%, -3.72%, and -6.62% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Gilead Sciences, Inc. (NASDAQ: GILD) shares accounts for 86.02% of the company’s 1.25B shares outstanding.

It has a market capitalization of $89.81B and a beta (3y monthly) value of 0.20. The stock’s trailing 12-month PE ratio is 16.01, while the earnings-per-share (ttm) stands at $4.50. The company has a PEG of 3.13 and a Quick Ratio of 1.27 with the debt-to-equity ratio at 1.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.97% over the week and 1.34% over the month.

Earnings per share for the fiscal year are expected to increase by 5.56%, and 5.02% over the next financial year. EPS should grow at an annualized rate of 5.12% over the next five years, compared to 1.55% over the past 5-year period.

Looking at the support for the GILD, a number of firms have released research notes about the stock. Truist stated their Hold rating for the stock in a research note on February 22, 2024, with the firm’s price target at $91-$82. Deutsche Bank coverage for the Gilead Sciences, Inc. (GILD) stock in a research note released on November 09, 2023 offered a Hold rating with a price target of $75. BofA Securities was of a view on September 08, 2023 that the stock is Buy, while HSBC Securities gave the stock Reduce rating on September 06, 2023, issuing a price target of $71. Barclays on their part issued Equal Weight rating on July 24, 2023.

Most Popular

Related Posts